CytRx Corporation Appoints Cary J. Claiborne to its Board of Directors and as Member of Audit Committee and Chairperson of Compensation Committee

CytRx Corporation welcomed Cary J. Claiborne to the Board of Directors. Claiborne brings to CytRx a wealth of experience in public company governance, finance and operational management. Claiborne is the Chief Operating Officer at Adial Pharmaceuticals Inc., where he also serves as a board director.

He is also a board director and audit committee chair at NeuroSense Therapeutics. Prior to joining Adial, Claiborne served as the Chief Financial Officer and board director at Indivior, PLC. Claiborne also served as CEO and a board director at New Generation Biofuels Inc. and MedicAlert Foundation, where he served as the chair of the audit and finance committees.

From 2011 to 2014, Claiborne was the Chief Financial Officer of Sucampo Pharmaceuticals Inc. Claiborne graduated from Rutgers University with a B.A. in Business Administration and holds an M.B.A. from Villanova University. He was previously a NACD Governance Fellow. Claiborne is serving on the CytRx Audit Committee and is the new Chairperson of the Compensation Committee.